Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients with HER2-Expressing Breast, Gastric and Other Solid Cancers at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

New research presented at the American Society of Clinical Oncology annual conference this month shares the comprehensive research program is underway to accelerate development of an investigational HER2-targeting antibody drug conjugate, DS-8201.